Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke
Zhuo Liu,Dandan Liu,Zhen-Ni Guo,Hang Jin,Tong Sun,Chunping Ni,Xiuli Yan
DOI: https://doi.org/10.2147/PGPM.S321084
2021-09-04
Pharmacogenomics and Personalized Medicine
Abstract:Zhuo Liu, 1, 2 Dandan Liu, 3 Zhen-Ni Guo, 2 Hang Jin, 2 Tong Sun, 4 Chunping Ni, 1, &ast Xiuli Yan 2, &ast 1 Fourth Military Medical University, School of Nursing, Xi'an, People's Republic of China; 2 Department of Neurology, The First Hospital of Jilin University, Changchun, People's Republic of China; 3 Physical Examination Center, The First Hospital of Jilin University, Changchun, People's Republic of China; 4 Cadre Ward, The First Hospital of Jilin University, Changchun, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiuli Yan Department of Neurology, the First Hospital of Jilin University, 71# Xinmin Street, Changchun, 130021, People's Republic of China Tel +86-15843079660 Fax +86-431-88782378 Email Chunping Ni Fourth Military Medical University, School of Nursing, 169# Changle Road West, Xi'an, 710032, People's Republic of China Tel +86-13572498128 Fax +86-29-84711715 Email Background: Deep vein thrombosis (DVT) is common among patients with stroke. However, the incidence of DVT in acute ischemic stroke patients treated with thrombolytic therapy and the risk factors associated with this condition are unknown. Objective: This study aimed to investigate the incidence and risk factors of DVT after thrombolysis in patients with acute ischemic stroke. Settings and Methods: We retrospectively reviewed the medical records of all patients with acute ischemic stroke who underwent ultrasonic examination after intravenous thrombolysis between April 2017 and December 2019 at the stroke center of the First Hospital of Jilin University, China. Color duplex ultrasound was used to diagnosis DVT in all patients within 72 h after intravenous thrombolysis. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for DVT. Results: Overall, 474 patients were included in the study. Of these, 75 (15.8%) developed DVT (95% confidence interval 12.5– 19.1). Older age was the risk factor that most significantly affected the development of DVT ( p = 0.001). Compared to patients younger than 60 years old, those aged 60– 69 years and ≥ 70 years had a higher risk of DVT, at rates of 2.201 (95% CI: 1.033– 4.689; p < 0.05) and 4.241 (95% CI: 2.016– 8.922; p < 0.001) times higher, respectively. Patients with higher triglyceride levels (odds ratio 0.545, 95% CI: 0.372– 0.799, p = 0.002) and longer activated partial thromboplastin time (OR 0.927, 95% CI: 0.862– 0.996, p = 0.040) were less likely to have DVT. Conclusion: DVT is a common complication among patients undergoing intravenous thrombolysis after acute ischemic stroke. Advanced age may increase the occurrence of DVT to some extent. For these patients, safe antiplatelet therapy should be explored and implemented as soon as possible. Keywords: acute ischemic stroke, deep vein thrombosis, incidence, risk factors, thrombolytic therapy Acute ischemic stroke is a major cause of mortality and morbidity worldwide. Patients admitted to the hospital with a stroke of recent onset are at risk of deep vein thrombosis (DVT), 1 even complicated by pulmonary emboli, which is a frequent, potentially fatal complication among incapacitated stroke patients. DVT is mainly caused by abnormal blood coagulation in the deep veins and venous reflux disease, which often occurs in the lower extremities. It is commonly seen in the muscular calf veins, fibular veins, and posterior tibial veins. 2 The incidence rate of DVT among post-stroke patients varies from 10% to 75%, depending on the method of diagnosis and the time of evaluation. 3 The most effective treatment for acute ischemic stroke is intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). It can effectively activate plasminogen within the fibrinolytic system, to maximally dissolve the thrombus. As a result, thrombolytic therapy may be regarded as a protective factor against DVT. However, a study revealed that thrombolytic therapy did not protect against DVT, with 21% of patients treated with rt-PA developing DVT, 4 at a rate almost equal to that of stroke patients managed without thrombolysis. In addition, several cross-sectional studies have shown that the incidence of DVT among patients with ischemic stroke treated with thrombolytic therapy was slightly higher than that among patients who did not receive thrombolytic therapy. 5–7 According to a meta-analysis, older age, diabetes mellitus, atrial fibrillation, paralysis, -Abstract Truncated-
pharmacology & pharmacy